Interestingly, in a previous study the prevalence of BCL2 mutations detected in FL tumor tissue samples was 12% at diagnosis and 53% at the transformation; and FL patients with BCL2 mutations had shortened survival and increased risk of histological transformation to aggressive B cell lymphomas (24). The gene discussed is BCL2; the disease is B-cell non-Hodgkin lymphoma.